Day One Biopharmaceuticals Has Collaborated With Sprint Bioscience For Its VRK1 Program; Day One Will Make An Upfront Payment Of $3M, Reimburse Sprint Bioscience For Preclinical R&D Expenses And Additional Milestone Payment Of $313M
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals has entered into a collaboration with Sprint Bioscience for its VRK1 program. Day One will make an upfront payment of $3M, reimburse Sprint Bioscience for preclinical R&D expenses, and make an additional milestone payment of $313M.
August 16, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Day One Biopharmaceuticals' collaboration with Sprint Bioscience for the VRK1 program involves significant financial commitments, including a $3M upfront payment and a potential $313M milestone payment.
The collaboration with Sprint Bioscience for the VRK1 program represents a significant financial commitment for Day One Biopharmaceuticals. The upfront payment of $3M, along with the potential milestone payment of $313M, could put pressure on the company's financial resources in the short term, potentially impacting its stock price negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100